George  de Urioste net worth and biography

George de Urioste Biography and Net Worth

Director of HeartBeam

George de Urioste combines over 30 years of experience in High Technology industry senior management. Previously, he had been involved in over 10 companies, holding positions including Board Director, Chief Operating Officer and Chief Financial Officer. From 1992 to 1998, he was Chief Financial Officer of Remedy Corporation (software), from 2000 to 2003, he was Chief Executive Officer of Aeroprise, Inc. (software), from 2004 to 2006 he was Chief Operating Officer and Chief Financial Officer for Chordiant Software, Inc. (software) In 2008, he was interim Chief Operating Officer and Chief Financial Officer for Marvell Technology, Inc.(semiconductors). From 2014 through 2018, he was Chief Financial Officer for Pluribus Networks, Inc. (software). From 2019 to 2020 he was Chief Financial Officer for 4iQ, Inc. (software) and is currently interim Chief Financial Officer for Mozilla, Inc. (software). Mr. de Urioste’s Board Director experience includes Audit Committee chairman roles for the following companies: Rainmaker Systems, Inc. (business outsourcing), from 2003 to 2005, Saba Software, Inc. (software) from 2008 to 2010, GCT, Inc. (semiconductors), from 2009 to 2011 Villa Montalvo (performing arts center), from 2011 to 2013, Bridgelux, Inc., from 2011 to 2016 (LED lighting), and Vendavo, Inc., from 2013 to 2014 (software). He was also chairman of the Board of Directors for Aeroprise, Inc. from 2000 to 2005 (software). He is currently a Board Director at Silicon Valley Directors Exchange, (a not-for-profit for Board education events). He has an undergraduate degree from University of Southern California and an MBA from University of California at Berkeley. Mr. de Urioste is also a Certified Public Accountant (inactive) in the State of California.

What is George de Urioste's net worth?

The estimated net worth of George de Urioste is at least $12.21 thousand as of December 17th, 2025. Mr. de Urioste owns 33,185 shares of HeartBeam stock worth more than $12,209 as of September 30th. This net worth approximation does not reflect any other investments that Mr. de Urioste may own. Learn More about George de Urioste's net worth.

How do I contact George de Urioste?

The corporate mailing address for Mr. de Urioste and other HeartBeam executives is 1000 CEDAR HOLLOW ROAD, MALVERN PA, 19355. HeartBeam can also be reached via phone at 610-729-7000 and via email at [email protected]. Learn More on George de Urioste's contact information.

Has George de Urioste been buying or selling shares of HeartBeam?

George de Urioste has not been actively trading shares of HeartBeam during the last ninety days. Most recently, George de Urioste sold 33,185 shares of the business's stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $2.83, for a transaction totalling $93,913.55. Learn More on George de Urioste's trading history.

Who are HeartBeam's active insiders?

HeartBeam's insider roster includes Tim Cruickshank (CFO), George de Urioste (Director), Richard Ferrari (Director), Michael Jaff (Director), Marga Ortigas-Wedekind (Director), and Branislav Vajdic (President, Director). Learn More on HeartBeam's active insiders.

Are insiders buying or selling shares of HeartBeam?

In the last year, HeartBeam insiders bought shares 7 times. They purchased a total of 1,118,750 shares worth more than $895,000.00. In the last year, insiders at the medical research company sold shares 3 times. They sold a total of 307,146 shares worth more than $1,077,090.03. The most recent insider tranaction occured on April, 16th when CFO Tim Cruickshank bought 31,250 shares worth more than $25,000.00. Insiders at HeartBeam own 18.0% of the company. Learn More about insider trades at HeartBeam.

Information on this page was last updated on 4/16/2026.

George de Urioste Insider Trading History at HeartBeam

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/18/2025Sell33,185$2.83$93,913.55View SEC Filing Icon  
12/17/2025Sell23,961$3.68$88,176.4833,185View SEC Filing Icon  
9/6/2024Sell1,674$2.34$3,917.1657,146View SEC Filing Icon  
8/26/2024Sell300$2.38$714.0066,514View SEC Filing Icon  
8/23/2024Sell2,500$2.30$5,750.0066,814View SEC Filing Icon  
9/28/2023Sell8,000$2.04$16,320.0041,629View SEC Filing Icon  
9/26/2023Sell5,000$2.09$10,450.0051,463View SEC Filing Icon  
9/22/2023Sell2,393$2.21$5,288.5356,463View SEC Filing Icon  
9/20/2023Sell883$2.46$2,172.1858,956View SEC Filing Icon  
9/18/2023Sell5,000$2.46$12,300.0059,839View SEC Filing Icon  
9/15/2023Sell4,269$2.43$10,373.6764,839View SEC Filing Icon  
9/13/2023Sell5,000$1.93$9,650.0074,108View SEC Filing Icon  
See Full Table

George de Urioste Buying and Selling Activity at HeartBeam

This chart shows George de Urioste's buying and selling at HeartBeam by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

HeartBeam Company Overview

HeartBeam logo
BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.
Read More

Today's Range

Now: $0.37
Low: $0.36
High: $0.38

50 Day Range

MA: $0.47
Low: $0.36
High: $0.59

2 Week Range

Now: $0.37
Low: $0.36
High: $4.00

Volume

4,039 shs

Average Volume

973,169 shs

Market Capitalization

$20.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A